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doi:10.1016/j.jfma.2011.10.003This article reviews human observations on pioglitazone and bladder cancer risk. The PROspec-
tive pioglitAzone Clinical Trial In macroVascular Events trial showed an imbalance in bladder
cancer between users of pioglitazone and placebo (14 versus six cases, p Z 0.069). However,
after excluding bladder cancer probably ascribed to other etiology, a blind assessment
concluded that the imbalance might not be related to pioglitazone. Epidemiologic studies con-
ducted in the United States and France using insurance databases independently suggested
that pioglitazone use for >2 years might confer a 20%e40% higher risk. Another study evalu-
ating bladder cancer risk in diabetic patients using the National Health Insurance in Taiwan
did not find any incident bladder cancer case among 422 pioglitazone users for a follow-up
of up to 3 years. Because observational studies may suffer from selection and information bias,
and inadequate adjustment for confounders may inflate the estimated risk, causal inference
from these studies should be interpreted with caution. While investigating cancer risk associ-
ated with a medication, indication bias should also be attended, especially when the medica-
tion is used at a late stage of the disease. Because pioglitazone is usually a second or third line
antidiabetic agent, the users are always characterized by older age, longer diabetes duration,
poorer glycemic control, and higher rates of complications and comorbidities. Biased estimates
will also result if these differences are not appropriately addressed in the analyses. Current
evidence neither concludes nor excludes a causal role of pioglitazone on bladder cancer. Clin-
ical trials aiming at evaluating the risk of cancer associated with a medication is not ethical
and may not be expected to provide an answer on the issue of pioglitazone-related bladder
cancer. However, a meta-analysis using all available clinical trials to compare the bladder cancer
risk between pioglitazone and comparators will be helpful. Well-conducted epidemiologicNational Taiwan University Hospital, Number 7, Chung-Shan South Road, Taipei 100, Taiwan.
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124 C.-H. Tsengobservational studies are probably other options. Because bladder cancer incidence and their
risk factors may differ significantly among different ethnicities, a clarification of such a link in
different ethnicities is needed, better by using long-term databases with large and represen-
tative sample size and appropriate adjustment for confounders. Furthermore, the interactions
with other comorbidities and concomitant medications should be addressed.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Peroxisome proliferator-activated receptor gamma (PPARg)
is a nuclear hormone receptor that acts as a transcription
factor. PPARg1 is expressed in several tissues including the
heart, skeletal muscle, kidney, pancreas, urothelium, and
intestine; but, PPARg2 (bearing additional 28 amino acids
at the N-terminus of PPARg1) is expressed exclusively in
adipose tissue.1 Activation of PPARg enhances insulin
sensitivity and improves blood glucose metabolism. There-
fore, its agonists have been developed for clinical use for
the control of hyperglycemia in patients with type 2 dia-
betes, a disease characterized by insulin resistance. Clini-
cally, a class of medications exerting PPARg agonistic
effects is known as the thiazolidinedione (TZD).
The first TZD, ciglitazone, was developed in 1980s but
was abandoned for marketing due to unexpected adverse
events.2 Three TZDs have ever been marketed and used
clinically, namely troglitazone, rosiglitazone, and pioglita-
zone. Troglitazone was marketed in 1997 but was with-
drawn from the world’s market in 2000 due to its
unexpected dreadful risk of liver failure.3 However, trogli-
tazone has never been approved for clinical use in Taiwan
before its worldwide withdrawal. Both rosiglitazone and
pioglitazone were approved by the U.S. Food and Drug
Administration (FDA) in 1999, but they were marketed in
Taiwan in 2001 and 2002, respectively. Rosiglitazone was
withdrawn from the market of Europe by the European
Medicines Agency (EMEA) in September 2010 for a possible
link with myocardial infarction.4
Recently, the potential link between pioglitazone and
bladder cancer risk has been enthusiastically discussed.
The health regulatory authority of France suspended the
use of pioglitazone on June 9, 2011, followed by its with-
drawal on July 11, 2011. These actions have caused panic to
the public, especially patients using pioglitazone and
physicians who have prescribed the medication. The FDA
and the EMEA have requested an amendment to the
package insert of pioglitazone for warning on the possible
risk of bladder cancer and asked for early identification of
bladder cancer cases. There are two main points as seen in
the current FDA recommendations5: (1) “Do not use pio-
glitazone in patients with active bladder cancer”; and (2)
“Use pioglitazone with caution in patients with a prior
history of bladder cancer. The benefits of blood sugar
control with pioglitazone should be weighed against the
unknown risks for cancer recurrence.”
It is deemed that a timely review of the current
evidence on the possible link between pioglitazone and
bladder cancer risk is urgently needed. Therefore, the
present article reviews available studies conducted in
humans on the related issues.PROactive study
In the PROspective pioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) study, although the use of
pioglitazone in patients with type 2 diabetes can signifi-
cantly reduce non-fatal myocardial infarction, stroke, and
all-cause mortality,6e8 a concern has arisen because more
bladder cancer cases developed in the pioglitazone group
than in the placebo group (14 vs. 6 cases, p Z 0.069).6,9
However, 11 out of these 20 cases had bladder cancer
diagnosed within 1 year of randomization into the study.6
After excluding these 11 cases, another case found to
have benign histology in the placebo group and those with
other known risk factors for bladder cancer (i.e., chronic
smoking, chronic bladder irritation, potential carcinogen
exposure, previous vesical tumor), there were only three
cases of bladder cancer left, two in the pioglitazone group,
and one in the placebo group.6,9 Therefore, the Data and
Safety Monitoring Committee6 concluded that “it is
improbable that the imbalance is related to pioglitazone
treatment.”
The PROactive study is probably the first clinical trial in
humans that brought into concern the possible link between
pioglitazone and bladder cancer, which had been demon-
strated in preclinical animal studies in male rats, but not in
female rats or in mice of both sexes.10 However, the
PROactive study was aimed at evaluating cardiovascular
outcomes as either primary or secondary end points, and
cancer risk was only monitored as one of the safety profiles.
Taking into account the low incidence of bladder cancer,
the PROactive study did not provide substantial statistical
power for a causal inference.U.S. pharmacy claims study
A U.S. study using the pharmacy claims database in
a retrospective cohort analysis did not find any association
between TZDs use and risk of cancers of the colorectum,
liver, bladder, pancreas, or melanoma.11 The estimated
relative risk for bladder cancer was 1.05 (0.71e1.54) after
adjustment for age, sex, schistosomiasis, and pelvic radia-
tion. However, this study has limitations of being unable to
discern pioglitazone from other TZDs, a small number of
bladder cancer cases (n Z 178), failure to consider
important risk factors for bladder cancer such as smoking,
some occupational exposure, renal function, and urolith-
iasis, and not considering the cumulative dose and duration
of exposure. Furthermore, the ascertainment and confir-
mation of the bladder cancer cases and the completeness
of case identification by using administrative databases are
not certain.
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A brief report using the FDA Adverse Event Reporting
System (AERS) suggested a significantly higher risk in pio-
glitazone users with an odds ratio of 4.30 (2.82e6.52).12
However, the results from AERS tend to be biased,
depending on the alertness and reporting willingness of the
physicians. If the reporting is not enforced by the law,
under-reporting can be expected. On the other hand, if the
association is overemphasized by the media or the medical
societies, an over-reporting of bladder cancer cases asso-
ciated with pioglitazone use will prevail.
Kaiser Permanente Northern California study
Under the request of the FDA in 2003, an ongoing 10-year
prospective observational study using the Kaiser Perma-
nente Northern California (KPNC) diabetes registry has
been proposed and supported by a grant from Takeda
Global Research & Development Center, Inc. to evaluate
whether pioglitazone use could be associated with bladder
cancer. The recent interim analysis did not find an overall
increase of bladder cancer risk associated with pioglitazone
use, but a significantly increased risk of 40% for prolonged
use of >2 years was noted.13 The study did not find any
interaction between sexes.
Because the study recruited patients from insurance
restricted to a localized region in the United States, the
representativeness of this sample for the entire U.S. pop-
ulation is surely in doubt. Neither selection bias nor infor-
mation bias could be excluded due to the inherent
limitations of an observational study. Furthermore, the
frequencies of missing data on potential confounders at
baseline are actually very high, making biased estimates to
be possible.
Although the KPNC study recruited approximately 10% of
the patients of Asian ethnicities,13 the results may not be
readily generalized to the Asian populations, who show
a lower risk of bladder cancer in general and may probably
have different risk factors.
French CNAMTS study
The French CNAMTS (Caisse Nationale d’Assurance Maladie
des Travailleurs Salarie´s) study, which covered approxi-
mately 86% of the French population, analyzed a retro-
spective cohort of the French health insurance databases
for a 4-year period from 2006 to 2009. They concluded that
a 1.22-fold higher risk of bladder cancer was noted among
155,535 pioglitazone users (of whom 175 bladder cancer
cases were found) out of 1,491,060 diabetic patients when
compared with nonusers.14 Like the KPNC study, the French
study also suggested a possible higher risk associated with
prolonged use of >2 years or a cumulative dose of
>28,000 mg, with respective hazard ratios of 1.36
(1.04e1.79) and 1.75 (1.22e2.50).14 However, unlike the
KPNC study, the French study showed a significant link only
in men, but not in women, when the analyses were con-
ducted in separate sexes.14
Based on the report, the French health regulatory
authority (Agence franc¸aise de se´curite´ sanitaire desproduits de sante´) unilaterally suspended the use of pio-
glitazone on June 9, 2011,15 prior to the decision of a then
ongoing review on the risk/benefit of pioglitazone by the
Committee for Medicinal Products for Human Use (CHMP) of
the EMEA starting in March 2011. France also withdrew the
use of pioglitazone unilaterally on July 11, 2011, before the
final decision made by the CHMP.
Following the French suspension, Germany suspended
the use of pioglitazone in new patients on June 10, 2011.16
Tunisia and Mauritius followed the footsteps of France by
suspending and withdrawing the use of pioglitazone.16
The CHMP summoned a meeting to discuss the bladder
cancer risk associated with pioglitazone on June 20e23,
2011, but no conclusion or recommendation was made after
this meeting.17 The decision of the CHMP was postponed
until July 21, 2011, with a recommendation that “benefit-
risk balance remains positive in a limited population of type
2 diabetics” and pioglitazone is contraindicated in patients
with current bladder cancer or a history of bladder cancer.18Taiwanese observations
By using the reimbursement databases of the National
Health Insurance (NHI), we recently demonstrated that
diabetic patients in Taiwan have a higher risk of bladder
cancer incidence than people without diabetes.19 In addi-
tion, we showed that male sex, nephropathy, and urinary
tract diseases including infections and stones were signifi-
cant risk factors for bladder cancer.19 After adjustment,
use of TZDs (including rosiglitazone and pioglitazone) were
actually associated with a lower, though insignificant, risk
of bladder cancer; and among 422 patients using pioglita-
zone, none had developed bladder cancer during the short
observation period of 3 years.19 Because the main purpose
of that study was to investigate the link between diabetes
and bladder cancer risk, we did not consider the cumulative
dose or duration of exposure for TZDs.19
It is interesting that we observed a decreasing risk of
bladder cancer with longer duration of diabetes, which is in
contrary to an increasing risk observed by Mackenzie and
colleagues.20 It should be noted that the design of the study
by Mackenzie and colleagues was case-control, and they
adjusted only for age, sex, smoking, body mass index and
urinary tract infection in multivariable models.20 Some
of the comorbidities that might be associated with both
diabetes duration and bladder cancer (thus can be
a confounder), such as renal disease, as shown in our study,19
were not considered for adjustment by Mackenzie and
colleagues.20 It is easy to explain the decreasing risk of
bladder cancer with longer duration of diabetes observed in
the Taiwanese study19: with prolonged diabetes duration,
the impact of age and chronic complications (especially
nephropathy and urinary tract diseases) may set in and
attenuate the association.
According to the National Reporting System of Adverse
Drug Reactions in Taiwan (supported by the Department of
Health of Taiwan), no case of bladder cancer associatedwith
pioglitazone use has ever been reported.21 However, under-
reporting is possible before the issue of such a link has been
brought into public attention by the media following the
French suspension of pioglitazone in June 2011.15
126 C.-H. TsengThe Taiwan FDA summoned a meeting to discuss on the
issue of pioglitazone and bladder cancer risk on June 22,
2011. The current recommendation of the Taiwan FDA fol-
lowed those of the USFDA and a labeling of warnings in the
Chinese package insert has also been requested.22
Discussion
Results from currently available studies on the link between
pioglitazone and bladder cancer are not consistent.
Whether the positive link in patients using pioglitazone in
some studies could be due to the drug per se, or due to the
underlying disease of diabetes, the interactions with other
concomitant drugs, the inherent flaws associated with
study designs and statistical analyses, or the different
ethnicities between studies, are worthy of discussion.
Diabetes
Diabetes per se may increase the risk of cancer, probably
via the activation of the Ras/Raf/mitogen-activated
protein kinase pathway in association with a reduction of
the expression of epidermal growth factor receptor.23 In
fact, epidemiologic studies also suggest an increased risk
of bladder cancer in diabetic patients,19,24,25 independent
of the commonly used oral antidiabetic agents or insulin.19
Therefore, if without appropriate adjustment and consid-
eration of the severity and duration of diabetes, an associ-
ation between bladder cancer and any of the anti-diabetic
agents may only reflect an effect of the disease per se or an
indication bias associated with the use of the medication
due to the severity of the disease.
Medications
TZDs are usually used as a second or a third line drug for the
treatment of diabetes. Its use always indicates a more
severe disease stage of diabetes, which may be associated
with older age, longer diabetes duration, poorer glycemic
control, higher prevalence of comorbidities, and the use of
multiple drugs. All of these can have an impact on the
development of bladder cancer. Therefore, if without
appropriate adjustment, indication bias associated with
pioglitazone use in patients with a late stage of diabetes
may result in biased estimates, which may reverse a lack of
association or even a protective effect to a higher risk
related to the use of the drug.
Because metformin may prevent some cancer and
sulfonylureas/insulin may be associated with a higher risk
of cancer,26,27 the interaction between pioglitazone and
other therapeutic agents used in the diabetic patients is
important and requires further clarification. For example,
in the KPNC study, pioglitazone users had significantly
higher rates of using sulfonylureas (87.2% vs. 58.6%) and
insulin (43.5% vs. 25.4%). These agents should have been
used for a long duration before pioglitazone was added.
Therefore, pioglitazone could also be a scapegoat or an
accomplice while the real culprit was not interrogated
intensively at the same time. If sulfonylureas/insulin did
increase the risk of bladder cancer, they must have alreadyposed a greater risk to the using patients and this should be
investigated simultaneously.
It is worthy to note that the daily dose of pioglitazone
used in the PROactive study was 45 mg,6 which was higher
than a daily dose of 30 mg commonly used in Taiwan.
Therefore, it is an interesting issue to explore whether the
higher dose used in Caucasians could possibly explain the
higher risk of bladder cancer among pioglitazone users.13Study designs and analyses
In clinical trials, confounders can always be controlled and
bias can be avoided by using a randomized, double-blind,
and placebo-control design. The temporal sequence of
cause and effect is easily discerned and is always correct.
However, it is unethical and impractical to conduct a clinical
trial for evaluating cancer risk associated with the use of
a medication. Observational epidemiologic studies remain
the mainstay in answering this kind of questions, but causal
inference from observational studies is always a great
challenge.
The PROactive study is the only clinical trial that has
provided an inconclusive hint for a possible link between
pioglitazone and bladder cancer. However, the small case
number of bladder cancer monitored as a safety profile did
not provide sufficient statistical power for causal infer-
ence. The results from the US KPNC13 and the French
CNAMTS14 studies similarly show a possible small increase in
bladder cancer risk associated with pioglitazone use.
However, both may suffer from bias and confounding
associated with the inherent limitations of observational
studies, and may not confirm a causal relationship based on
all stringent epidemiologic criteria, including strength,
consistency, specificity, temporality, biologic gradient,
plausibility, and coherence.28
Cigarette smoking and occupational or environmental
exposure to carcinogenic chemicals, such as aniline dyes,
cyclophosphamide, aromatic amines, and arsenic, are well
-recognized risk factors for bladder cancer.20,29,30 However,
these were not satisfactorily adjusted for either in the
KPNC study, the French CNAMTS study, or the other
observational studies. With regard to smoking, only infor-
mation on current smokers was reported in the KPNC study;
therefore, cigarette smoking was only partially adjusted. It
is not known how accurately this information was collected
and whether information bias could exist. The CNAMTS or
other observational studies did not adjust for smoking.
The study by Tseng19 in Taiwan was not primarily aimed
at evaluating the association between the use of antidia-
betic drugs and bladder cancer. Therefore, the case
number of pioglitazone users was too small to provide
sufficient statistical power. However, the Taiwanese study
confirmed that nephropathy and urinary tract diseases,
including stones and infection, are important risk factors
for bladder cancer.19 Diabetic patients may also have
a higher prevalence of these risk factors and they may also
use more medications than nondiabetic individuals
because of a higher prevalence of other comorbidities. If
these potential confounders are not adequately adjusted,
biased estimation of the associated risk even in an oppo-
site direction would result. For example, if we only
Pioglitazone and bladder cancer in human studies 127considered an adjustment for age, sex, and hypertension
by using the NHI database, a higher but insignificant risk of
bladder cancer could be seen in patients using TZDs
(January 2011).
A recently published Letter to the Editor31 argued
against the use of time-dependent pioglitazone usage in
Cox models for the possibility of wrong conclusion on its
association with cancer risk. Analyses using time-varying
incidence of cancer may also lead to detection bias.32
Both the KPNC study13 and the CNAMTS study14 used time-
dependent pioglitazone exposure for analyses. It is not
known whether this would have led to biased or incorrect
estimates in the studies.
Overfitting of regression models may also lead to a bias
against the null.33,34 Whether including too many variables
in the full models in the KPNC study may also lead to such
a bias is not known (although it was claimed to be
unlikely).13 Multiple comparisons in the KPNC study might
also have led to an incorrect rejection of the null hypoth-
esis among a set of statistical inferences just by chance.
Therefore, a stronger level of significance or a smaller p
value should be observed to make an inference of signifi-
cant association between pioglitazone use and bladder
cancer in the KPNC study.13
The KPNC study suffered from severe incomparability in
baseline characteristics between the pioglitazone ever-
users and never-users and the rates of missing data are
very high in most of the baseline characteristics, which
could have resulted from the use of self-reported personal
history and the incompleteness of the insurance data-
bases. Although the investigators tried their best to
correct for these potential biases, it should be noted that
biases may not always be corrected after data collection.
It is also interesting to note that the rate of congestive
heart failure in the pioglitazone users was significantly
lower than nonusers in the KPNC study (3.2% vs. 6.8%,
p < 0.001). This is somewhat against our common sense
that pioglitazone is associated with such a risk.6,35
Although pioglitazone users might be younger and there-
fore less prone to congestive heart failure in the KPNC
study, a careful look into the possibility of selection and
information bias is required.
According to French regulation, a personal medical
database can only be stored for a maximum of 4 years;
therefore, the investigators could only analyze the data-
bases within a short period of time from 2006 to 2009.
Furthermore, the findings derived from a retrospective
study, the lack of an appropriate adjustment for potential
confounders (such as smoking, renal function, or urinary
tract disease), and the potential selection and information
bias associated with the CNAMTS study should better be
confirmed with more evidence.
It should also be noted that the evidence for cardio-
vascular risk associated with rosiglitazone leading to its
withdrawal in Europe was mainly derived from clinical
trials.4 However, the current evidence for the link between
pioglitazone and bladder cancer was mainly derived from
observational studies. The level of evidence from obser-
vational studies is always lower than that from clinical
trials. Therefore, a meta-analysis using all available clinical
trials to compare the bladder cancer risk between piogli-
tazone and its comparators is urgently needed.Different ethnicities and sexes
According to the Taiwan Cancer Registry, the age-
standardized (to the World Health Organization 2000 stan-
dard population) bladder cancer incidence in the year 2007
was 10.5 and 4.2 per 100,000 people for Taiwanese men and
women, respectively.36,37 In the United States, the inci-
dence rates among different ethnicities differ markedly,
with Caucasians having the highest incidence, followed by
blacks, and the other ethnicities.38 In 2007, Caucasian men
and women showed an age-adjusted incidence of approxi-
mately 27 and 6.5 per 100,000 people, respectively.38
Whether the different incidences between our Taiwanese
population19 and Caucasians13,14 could be explained by the
different genetic backgrounds remains to be answered. It is
possible that differences in dietary components and socio-
economic and cultural backgrounds between different
ethnicities could play some role on the different link.
Universally, men have a higher risk of bladder cancer than
women in various ethnicities.19,38 Therefore, factors related
to sex, either genetically or environmentally linked, can
play some role on the development of bladder cancer. The
French CNAMTS study showed that the link between piogli-
tazone and bladder cancer was only observed in men but
not in women, but the U.S. KPNC study suggested a lack of
interaction between sexes. Therefore, these contradictory
findings with regard to sex13,14 require further exploration.
Risk of bladder cancer versus benefits
in cardiovascular disease
Pioglitazone reduces the risk of all-cause mortality,
nonfatal myocardial infarction, or stroke as secondary
endpoints by 16% (p Z 0.027),6 prevents recurrent fatal/
nonfatal myocardial infarction by 28% (p Z 0.0453),35 and
reduced fatal or nonfatal stroke by 47% (pZ 0.0085)7 in the
PROactive study. Pioglitazone is also effective to postpone
the permanent use of insulin,6 to improve lipid profile, and
to further reduce blood glucose level when metformin and/
or sulfonylurea fail.39
Weighing the beneficial effects of pioglitazone on
cardiovascular disease and glycemic control against the yet
unconfirmed possible risk of bladder cancer, it may not be
the best option to withdraw pioglitazone before the small
bladder cancer risk is confirmed. To abruptly discontinue its
use under panic in the diabetic patients is not recom-
mended, because this can probably lead to an uncontrol-
lable blood glucose level and unpredictable risk of
cardiovascular events. The repository for changing to other
oral antidiabetic agents in patients who have been put on
pioglitazone as a third line treatment is actually limited.
Insulin may be needed to control hyperglycemia after the
withdrawal from pioglitazone. However, it should also be
stressed that neither insulin nor sulfonylurea has been
proved to be safe without risk of cancer development.26,40,41
More evidence on mechanisms needed
It would also be interesting to know whether another
medication of the same class, i.e., rosiglitazone, would
Table 1 Main findings from human observations of pioglitazone or TZD use and bladder cancer risk.
Year
[Reference]
Name or source
of study
Study design Numbers of cases/follow-up
duration
Relative risk estimates
(95% CI)
Other remarks
2005 [6] PROspective pioglitAzone
Clinical Trial In
macroVascular Events study
Report of serious adverse
events in a clinical trial
Case numbers for
pioglitazone users and
placebo users were 2,605
and 2,633, respectively.
Average follow-up: 34.5
mos.
Bladder cancer cases
(percentage) in pioglitazone
group versus placebo group:
14 (0.5%) versus 6 (0.2%)
(p > 0.05).
After excluding bladder
cancer cases probably
attributed to other etiology,
the Data and Safety
Monitoring Committee
concluded that bladder
cancer might not be related
to pioglitazone.
2008 [11] U.S. pharmacy claims study Retrospective cohort study
using U.S. population-based
pharmacy claims databases
178 bladder cancer cases
among 191,223 diabetic
patients, median follow-up:
3.9 yrs.
TZD: 1.05 (0.71e1.54) The adjusted relative risk
was estimated for TZD use
(not specifically for
pioglitazone) after
excluding patients exposed
to insulin alone.
2011 [12] USFDA Adverse Event
Reporting System analysis
A spontaneous adverse
event reporting system for
medications from January
2004 to December 2009
Among 86,987 reports of
adverse events, there were
37,841 reports concerning
pioglitazone. Among 93
reports of bladder cancer,
31 concerning pioglitazone.
4.30 (2.82e6.52) Significantly higher risk of
bladder cancer in
pioglitazone users.
However, reporting bias
should be considered.
2011 [13] Kaiser Permanente Northern
California study (interim
report)
Prospective cohort study
using Kaiser Permanente
Northern California diabetes
registry
Among 193,099 diabetic
patients, 30,173 were ever
treated with pioglitazone.
Bladder cancer cases among
ever users and nonusers
were 90 and 791,
respectively; with
estimated incidence of 81.5
and 68.8 per 100,000
person-yrs, respectively.
Median follow-up from
cohort entry: 9.3 (range:
0.1e11.3) and 6.2 (0.1e
11.3) yrs, respectively.
1.2 (0.9e1.5) No overall significantly
increased risk observed, but
a significant 40% higher risk
can be seen for use of
pioglitazone>2 yrs.
2011 [14] French CNAMTS study Retrospective cohort study
using the French health
insurance databases within
a 4-year period from 2006 to
2009
Among 1,491,060 patients
with diabetes, 155,535 were
pioglitazone users and
1,335,525 were non-users.
The bladder cancer cases
were 175 and 1,841,
respectively.
1.22 (1.05e1.43) Dose-response relationship
was observed but sex-
specific analyses showed
significant risk in men only,
with relative risk of 1.28
(1.09e1.51).
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Pioglitazone and bladder cancer in human studies 129have any effect on bladder cancer. According to our
recently published papers,19,42 a lower but insignificant risk
of bladder cancer19 and prostate cancer42 was observed for
either rosiglitazone or pioglitazone. A meta-analysis,
including 80 clinical trials using rosiglitazone with a dura-
tion >24 weeks, suggested that rosiglitazone use was
associated with a significantly lower risk of cancer inci-
dence than the control group (0.23 versus 0.44 per 100
person-years, p < 0.05).43 However, this study did not
specifically analyze bladder cancer.
Actually, TZDs with PPARg agonistic activity may show
anticancer effects in in vitro studies,44 and there is no
evidence supporting an increased cancer risk related to
PPARg agonism. If pioglitazone does increase the risk of
bladder cancer, a mechanism other than PPARg activation
might be responsible, as shown in animals.45 In rats, the
prevention of pioglitazone-induced bladder tumor by
acidifying the urine is not due to an effect on PPARg ago-
nism or mitogenic potential, but probably related to drug-
induced compositional changes in the urine.45
The urinary bladder of diabetic patients with poor gly-
cemic control would be exposed to high levels of glucose
excreted from the urine. One of the mechanisms related to
a possible increased risk of bladder cancer in the diabetic
patients is the glucose-induced carcinogenicity. If this is the
case, long-term glycemic control per se will be a significant
risk factor for bladder cancer and should be considered for
adjustment in future studies. Taking into account the
recent warning of increased bladder cancer risk associated
with the use of sodium-dependent glucose cotransporter 2
inhibitors (a class of oral antidiabetic drugs under devel-
opment with a novel mechanism of inhibiting glucose
reabsorption from the kidney),46 a glucose-induced mech-
anism on bladder cancer cannot be excluded.Summary
The main findings from human observations on the issue of
pioglitazone use and bladder cancer risk as discussed in this
article are summarized in Table 1. In humans, bladder
cancer incidence differs among different ethnicities, and
men consistently show a higher risk than their female
counterparts within the same ethnicities. Caucasians have
significantly higher incidence of bladder cancer than other
ethnicities, including blacks and Asians. Clinical trials
aimed at evaluating the link between pioglitazone use and
bladder cancer risk are lacking but will not be practical or
feasible for future study. However, a meta-analysis using all
available clinical trials to compare the bladder cancer risk
between pioglitazone and its comparators will be helpful.
Observational epidemiologic studies remain the main
source for providing evidence, but currently available
analyses neither confirm nor exclude such a possible link.
Because both diabetes per se and comorbidities highly
prevalent in diabetic patients can be significant risk factors
for bladder cancer, causal inferences from observational
studies without considering the representativeness of study
subjects or adequate adjustment for confounders may
result in biased estimates, which may even be in the
opposite direction. Furthermore, findings from studies
conducted in Caucasians who have a higher risk of
130 C.-H. Tsengdeveloping bladder cancer and may probably have different
risk factors should not be immediately generalized to other
ethnicities without sufficient evidence. Because the link
between therapeutic agents and cancer risk is always of
high concern to the public, a clarification of the link
between pioglitazone use and bladder cancer risk in
different ethnicities is urgently needed.
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